Nevertheless, data have shown therapeutic benefits of the GPER-selective agonist G-1 in multiple disease models, ranging from multiple sclerosis to atherosclerosis to melanoma and pancreatic cancer, to diabetes and obesity. The gene discussed is GPER1; the disease is obesity due to melanocortin 4 receptor deficiency.